Fluorofenidone protects liver against inflammation and fibrosis by blocking the activation of NF‐κB pathway

Despite the increasing understanding of the pathophysiology of hepatic fibrosis, the therapies to combat it remain inadequate. Fluorofenidone (AKF‐PD) is a novel pyridone agent able to ameliorate hepatic fibrosis in an experimental hepatic fibrosis model induced by dimethylnitrosamine. However, the...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The FASEB journal 2021-07, Vol.35 (7), p.e21497-n/a
Hauptverfasser:	Tu, Sha, Jiang, Yanzhi, Cheng, Haihua, Yuan, Xiangning, He, Ying, Peng, Yu, Peng, Xiongqun, Peng, Zhangzhe, Tao, Lijian, Yang, Huixiang
Format:	Artikel
Sprache:	eng
Schlagworte:	AKF‐PD inflammation liver fibrosis NF‐κB
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!